Blog Archives

Therapies that promote progressive multifocal leukoencephalopathy (PML)

August 23, 2019 – Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal viral disease characterized by progressive damage or inflammation of the white matter of the brain at multiple locations (i.e., multifocal). It is caused by the JC virus,

Read more ›

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , ,

With Infliximab (Flixabi), a huge biosimilar medicine has been approved in the European Union (EU)

 June 22, 2016 – The European Medicines Agency (EMA) has approved, as of the end of May 2016, Infliximab (Flixabi). Infliximab (Flixabi) is a monoclonal antibody that has been designed to attach to a protein called tumour necrosis factor-alpha (TNF-alpha) and block its activity.

Read more ›

Tags: , , , , , , , , , , , ,

Tumor Necrosis Factor (TNF) blockers, Azathioprine and/or Mercaptopurine: Update on Reports of Hepatosplenic T-Cell Lymphoma (HSTCL) in Adolescents and Young Adults

April 15, 2011 – The American Food and Drug Adeministration (FDA) informed today that it  continues to receive reports of a rare cancer of white blood cells (known as Hepatosplenic T-Cell Lymphoma or HSTCL) primarily in adolescents and young adults being treated for Crohn’s disease and ulcerative colitis with medicines known as tumor necrosis factors (TNF) blockers,

Read more ›

Tags: , , , , , , , , ,

Boxed Warning Updated: TNF Blockers and Cancer Risks in Children

November 3, 2009 – As we learn from it’s todays announcement, FDA is requiring stronger warnings about an increased risk of lymphoma and other cancers in children and adolescents who are treated with drugs that block tumor necrosis factor. TNF blockers include Infliximab [Remicade], Etanercept [Enbrel], Adalizumab [Humira], Certolizumab [Cimzia],

Read more ›

Tags: , , , , , , , , ,

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Ancestry launches DNA health service that will compete with 23andMe October 15, 2019
    Ancestry has long appealed to people eager to learn about their family roots. Now the company known for its popular DNA kits is diving into a new area of discovery—health.
  • Improving research with more effective antibodies October 15, 2019
    A new study points to the need for better antibody validation, and outlines a process that other labs can use to make sure the antibodies they work with function properly.
  • New DNA 'clock' could help measure development in young children October 15, 2019
    Scientists have developed a molecular "clock" that could reshape how pediatricians measure and monitor childhood growth and potentially allow for an earlier diagnosis of life-altering development disorders.
  • DNA fracturing rewires gene control in cancer October 15, 2019
    Understanding the mechanisms that mediate widespread DNA damage in the cancer genome is of great interest to cancer physicians and scientists because it may lead to improved treatments and diagnosis. In this study, a multi-institutional team led by researchers at Baylor College of Medicine has brought attention to genomic structural variation as a previously unappreciated […]
  • Most genetic studies use only white participants – this will lead to greater health inequality October 15, 2019
    Few areas of science have seen such a dramatic development in the last decade as genomics. It is now possible to read the genomes of millions of people in so-called genome-wide association studies. These studies have identified thousands of small differences in our genome that are linked to diseases, such as cancer, heart disease and […]
Top